通过检测循环肿瘤DNA对复发/难治性弥漫大B细胞淋巴瘤患者进行风险分层
本研究评估基线循环肿瘤DNA(ctDNA)在复发/难治性弥漫大B细胞淋巴瘤(R/R DLBCL)中的预后价值。在33例可评估生物标志物的患者中,高基线ctDNA(高于中位数)独立预测更短的无进展生存期(校正HR 0.18,95%CI 0.05-0.65)和总生存期(校正HR 0.20,95%CI 0.06-0.68)。基线ctDNA评估可能识别高进展风险患者,应进一步评估作为监测工具。
要点
- 基线ctDNA水平与LDH浓度、既往治疗线数、分期和IPI评分相关。
- 高基线ctDNA独立预测更短PFS(校正HR 0.18,95%CI 0.05-0.65)和OS(校正HR 0.20,95%CI 0.06-0.68)。
- 达到完全缓解(CR)的患者ctDNA MMPM下降幅度显著大于未达CR者(P=0.0025)。
核心结论
- 基线ctDNA评估可能识别R/R DLBCL中高进展风险患者,应进一步评估作为监测工具。
研究设计与样本
- 评估基线ctDNA以识别接受polatuzumab vedotin联合苯达莫司汀+利妥昔单抗(BR)或单用BR后高复发风险的R/R DLBCL患者。
- 患者为不适合移植且既往接受≥1线治疗者。
- ctDNA检测基于DLBCL复发突变基因定制面板,测量基线和治疗结束时(EOT)每毫升突变分子数(MMPM)。
- 生物标志物可评估患者33例;有基线和EOT样本者23例。
- 试验注册号NCT02257567。
主要发现
- 基线ctDNA水平与血清LDH浓度、既往治疗线数、分期和IPI评分相关。
- 校正既往治疗线数≥2、IPI评分≥3和LDH高于正常上限后,高(高于中位数)基线ctDNA MMPM独立预测更短PFS(校正HR 0.18,95%CI 0.05-0.65)和OS(校正HR 0.20,95%CI 0.06-0.68)。
- 在23例有基线和EOT样本的患者中,完全缓解(CR)者(n=13)ctDNA MMPM下降幅度显著大于未达CR者(n=10),P=0.0025。
关键数值与推荐
- 高基线ctDNA定义为高于中位数的MMPM。
- 校正因素包括既往治疗线数≥2、IPI评分≥3和LDH高于正常上限。
临床怎么用
- 原文结论认为基线ctDNA评估可能识别高进展风险患者,应进一步评估作为R/R DLBCL的监测工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have heterogeneous outcomes; durable remissions are infrequently observed with standard approaches. Circulating tumor DNA (ctDNA) assessment is a sensitive, potentially prognostic tool in this setting. We assessed baseline ctDNA to identify patients with R/R DLBCL at high risk of relapse after receiving polatuzumab vedotin and bendamustine plus rituximab (BR) or BR alone. Patients were transplant ineligible and had received ≥1 prior line of therapy. The ctDNA assay, based on a customized panel of recurrently mutated genes in DLBCL, measured mutant molecules per mL (MMPM) at baseline and end of treatment (EOT). Endpoints included progression-free survival (PFS) and overall survival (OS) in subgroups stratified by baseline ctDNA and log-fold change in ctDNA at EOT vs baseline. In biomarker-evaluable patients (n = 33), baseline ctDNA level correlated with serum lactate dehydrogenase (LDH) concentration, number of prior therapies, stage, and International Prognostic Index (IPI). After adjusting for number of prior therapies ≥2, IPI score ≥3, and LDH above the upper limit of normal, high (greater than median) baseline ctDNA MMPM was independently prognostic for shorter PFS (adjusted hazard ratio [HR], 0.18 [95% CI, 0.05-0.65]) and OS (adjusted HR, 0.20 [95% CI, 0.06-0.68]). In 23 patients with baseline and EOT samples, a significantly greater decrease in ctDNA MMPM was observed in patients with complete response (CR) (n = 13) than those without CR (n = 10); P = .0025. Baseline ctDNA assessment may identify patients at high risk of progression and should be further evaluated as a monitoring tool in R/R DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT02257567.
引用
- Herrera AF, Tracy S, Croft B, et al. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Adv. 2022. PMID: 35086141. doi:10.1182/bloodadvances.2021006415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。